Ultrasound-guided thermal ablation for papillary thyroid microcarcinoma: a multicenter retrospective study
Xiao-Jing Cao,Ming-An Yu,Ya-Lin Zhu,Lu Qi,Zhi-Bin Cong,Guo-Zhen Yan,Juan Liu,Hong-Ling Wang,Geng Liu,Jian-Qin Guo,Ying Hao,Zhong-Hua Wang,Xue Wang,Jun-Feng He,Aini Shataer,Xiao-Fang Liu,Zhen-Long Zhao,Ying Wei,Li-Li Peng,Yan Li,Shu-Rong Wang,Ying Che
DOI: https://doi.org/10.1080/02656736.2021.1936218
2021-01-01
International Journal of Hyperthermia
Abstract:Ultrasound-guided thermal ablation (including microwave ablation [MWA] and radiofrequency ablation [RFA]) has emerged as a remarkable technology for the treatment of benign and malignant diseases. The objective of this multicenter study was to assess the efficacy and safety of thermal ablation in a large cohort of patients with papillary thyroid microcarcinoma (PTMC).Retrospective study of 725 patients who underwent MWA/RFA at 11 centers between March 2015 and March 2020. The mean age of patients was 46 ± 11 years (range, 22–81); the mean follow-up time was 21 ± 13 months (range, 6–60). Changes in size of tumor, the rates of tumor disappearance, disease progression, and complications were assessed.From 6 months post-ablation, the size of tumors was significantly reduced compared with those recorded pre-ablation (p < 0.001 for all). Five hundred and fifteen (71.0%) PTMCs had completely disappeared as assessed by ultrasound examination. Six (0.8%) patients developed disease progression post-ablation; of these, 5 (0.7%) patients developed new PTMCs, while one (0.1%) patient developed cervical lymph node metastasis. Nineteen (2.6%) patients developed complications post-ablation; of these 14 (1.9%) patients developed voice hoarseness, 4 (0.6%) developed hematoma, and one (0.1%) patient developed cough.Ultrasound-guided thermal ablation represents an effective and safe treatment for patients with PTMC besides active surveillance and surgery.
oncology,radiology, nuclear medicine & medical imaging